InterCure Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
INCR Nasdaq 2830 www.intercure.co

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for InterCure Ltd.

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement - Mar 3rd, 2026 2:46 pm
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million - Feb 19th, 2026 5:00 am
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million - Feb 19th, 2026 5:00 am
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - Nov 3rd, 2025 6:30 am
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow - Oct 8th, 2025 7:40 am
Middle Eastern Penny Stocks With Market Caps Over US$1M - Sep 29th, 2025 3:04 am
Sector Update: Health Care Stocks Mixed Late Afternoon - Sep 19th, 2025 2:02 pm
InterCure Enters Premium US Cannabis Market With ISHI Deal - Sep 19th, 2025 8:06 am
InterCure to Acquire Cannabis Brand Botanico in Two-Phase Deal - Sep 19th, 2025 8:03 am
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands - Sep 19th, 2025 6:48 am
August 2025's Middle Eastern Penny Stocks: Discovering Hidden Opportunities - Aug 8th, 2025 3:04 am
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - May 1st, 2025 2:00 pm